Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Figure out How to Amplify the Resale Worth of Your Kona SUV - 2Concern for couple jailed in Tehran as British embassy closes
- 3Rediscovering Imagination in Adulthood: Individual Creative Excursions
- 4Bolsonaro briefly leaves Brazilian prison for medical tests after a fall from his bed
- 5Boeing's troubled capsule won't carry astronauts on next space station flight
- Flourishing in a Cutthroat Work Market: Vocation Methodologies
- Doomed SpaceX Starlink satellite photographed from orbit
- 'Stranger Things' star debunks claims of 'unseen footage' from Season 5, Volume 2 as backlash intensifies ahead of the series finale
- Higher cost, worse coverage: Affordable Care Act enrollees say expiring subsidies will hit them hard
- Defense Minister Katz moves to extend IDF service to 36 months
- The Universe of Impeccable Pearls: A Manual for Valuable Gems
- Toddler given just 3 years to live after strange symptoms makes full recovery
- Beneficial Growing Conditions in West Africa Weigh on Cocoa Prices
- Israel's ban on unsupervised reporters in Gaza causes strategic harm to legitimacy
